FreMon Scientific has entered into a Sponsored Validation Study Agreement with the MedStar Georgetown University Hospital Cell Therapy Manufacturing Facility.

This collaboration will validate the performance of ZipThaw for off-label use in cell and gene therapy — a major milestone toward expanding its role in advanced therapeutic applications.

• Phase 1 – Bench Validation: Paired comparison of post thaw viability of ZipThaw and 37°C water bath thawing of cryopreserved hematopoietic progenitor cells (HPCs).
• Phase 2 – Lifecycle Validation: Paired comparison using identical clinical HPC products.

All work will be performed under the highest scientific and quality rigor standards. The study results will provide valuable data supporting the use of ZipThaw in clinical cell therapy programs.

We’re proud to advance safe, consistent, and innovative thawing technology for the growing field of cell and gene therapy.